CD19 and acute lymphoblastic leukemia: The clinical success of CAR T cell therapy eventually culminated in the FDA approval of two CD19-specific CAR T cell products, namely tisagenlecleucel for r/r ALL and r/r large B cell lymphoma and axicabtagene cliloleucel for r/r large B cell lymphoma [17,18].